207 Central-acting therapeutics alleviate respiratory weakness caused by heart failure–induced ventilatory overdrive.
http://stm.sciencemag.org/content/9/390/eaag1303
206 BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure.
http://stm.sciencemag.org/content/9/390/eaah5084
205 Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1615664
204 Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
http://www.nejm.org/doi/full/10.1056/NEJMoa1615758
203 Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
http://www.nejm.org/doi/full/10.1056/NEJMoa1614062
202 Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
http://www.nejm.org/doi/full/10.1056/NEJMoa1701488
201 Neutrophil stunning by metoprolol reduces infarct size.
https://www.nature.com/articles/ncomms14780
200 Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
http://www.nejm.org/doi/full/10.1056/NEJMoa1613627
199 A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure.
http://www.nejm.org/doi/full/10.1056/NEJMoa1610426
198 Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602954
|
